Related Experiment Video
Updated: Jun 4, 2026

Quantifying Inferior Vena Cava Compliance and Distensibility in an In Vivo Ovine Model Using 3D Angiography
Published on: April 26, 2024
The Contegra conduit in the right ventricular outflow tract is an independent risk factor for graft replacement
Stefano Urso1, Filip Rega, Bart Meuris
1Department of Cardiac Surgery, University Hospital Gasthuisberg, Leuven, Belgium. stefano_urso@inwind.it
Insights
The Contegra conduit, a bovine jugular vein graft, showed a higher incidence of graft replacement compared to homografts in right ventricle outflow tract reconstructions. Patients receiving the Contegra conduit were over twice as likely to need re-operation.
Area of Science:
- Cardiovascular Surgery
- Biomaterials in Medicine
- Congenital Heart Disease Treatment
Background:
- Valved conduits are essential for right ventricle outflow tract (RVOT) to pulmonary artery continuity in congenital heart diseases.
- Graft replacement is a significant concern in RVOT reconstruction.
Purpose of the Study:
- To compare graft replacement rates between the Contegra conduit (bovine jugular vein graft) and homografts in RVOT reconstructions.
- Identify risk factors for graft replacement in RVOT conduits.
Main Methods:
- Retrospective review of 347 RVOT conduits (Contegra: 54, Homografts: 293) implanted between 1989-2003.
- Follow-up of 323 patients (median age 12.7 years) with 99.4% completeness (mean 5.9 years).
- Analysis of indications including Tetralogy of Fallot, Ross operation, and others.
Main Results:
- Freedom from graft replacement at 10 years was lower for Contegra (63.5%) versus homografts (81.4%) (p < 0.001).
- Independent predictors for graft replacement included smaller graft size (≤ 20 mm), younger age (≤ 10.4 years), non-anatomical graft position, and use of the Contegra conduit.
- Multivariable analysis confirmed Contegra conduit use as an independent risk factor (HR 3.7).
Conclusions:
- The Contegra conduit is an independent risk factor for graft replacement in RVOT reconstructions.
- Patients receiving Contegra conduits face a significantly higher likelihood of re-operation compared to those receiving homografts.
- Graft size, patient age, and graft position also significantly influence the need for replacement.
Objective:
A large spectrum of congenital heart diseases requires valved conduits to establish an anatomical continuity between the right ventricle outflow tract (RVOT) and the pulmonary artery. The aim of the present study was to compare the incidence of graft replacement in patients receiving the Contegra conduit (bovine jugular vein graft) with that in patients receiving a homograft implanted in the RVOT.
Methods:
We reviewed a total of 347 conduits (Contegra 54; homografts 293) implanted in the RVOT from 1989 to 2003 in 323 patients (median age 12.7 years, range 4 days-69 years). Indications were Tetralogy of Fallot (n = 148), Ross operation (n = 89), truncus arteriosus communis (n = 47), pulmonary valve atresia (n = 30), double-outlet right ventricle (n = 15), transposition of the great arteries (n = 12), and endocarditis (n = 6). Follow-up was 99.4% complete (mean time: 5.9 years; range: 0-14.2 years).
Results:
Freedom from graft replacement at 1, 5, and 10 years of follow-up in the Contegra and homograft groups were 98.1 ± 1.9%, 78.3 ± 5.8%, and 63.5 ± 7.2% and 99.6 ± 0.4%, 94.0 ± 1.6%, and 81.4 ± 3.4%, respectively (log-rank test, p < 0.001). Independent predictors of graft replacement of the whole sample population were: graft size ≤ 20 mm (hazard ratio (HR) 3.6), age ≤ 10.4 years (HR 3.0), the non-anatomical position of the graft (HR 2.9), and the use of the Contegra conduit (HR 2.5). The multivariable analysis carried out on the propensity-score-matched population confirmed three independent predictors of graft replacement: graft size ≤ 20 mm (HR 8.0), the non-anatomical position of the graft (HR 2.3), and the use of the Contegra conduit (HR 3.7).
Conclusions:
Besides size of the graft, age of the patients, and the non-anatomical position of the graft, the use of the Contegra conduit was found to be an independent risk factor for graft replacement in the RVOT. Patients receiving this conduit were more than twice as likely to undergo re-operation for graft replacement as those receiving a homograft.
Related Concept Videos
Mitral Regurgitation I: Introduction
Aneurysm III: Interprofessional Care
Aortic Regurgitation I: Introduction

